Triple Ring Technologies
39655 Eureka Dr, Newark, CA, 94560, United States
Overview
Triple Ring Technologies is an on-demand core technology and product creation lab serving partners in regulated industries. They have successfully completed over 300 projects for confidential clients. Triple Ring has technology creation facilities in Silicon Valley and Boston. Their headquarters (Newark, CA) is 96,000 sq. ft. of flexible space that includes laboratories for electronics, optics, radiation source development, mechanical prototyping; systems integration, client drop-in offices; and pilot manufacturing. They build regulated technologies and complex products and offer a full range of related technical and business services: analysis and creation of intellectual property; development and implementation of technology strategy; design and development of engineering prototypes and released products; feasibility studies and testing; due diligence and situation analysis; and advisory services on regulatory compliance and technology pathways. Above all, they work collaboratively to build novel technologies and products.
- Total investments
- 2
- Lead investments
- 0
- Investments · 12mo
- 0
- Active investors
- 5
Sector focus
- Market Research
- Medical Device
- Product Design
Investment portfolio
- AiM Medical Robotics
Participated · Seed · Mar 2022
AiM Medical Robotics is building a compact, portable robotic platform that operates directly inside an MRI scanner, giving neurosurgeons continuous, real-time imaging while they position instruments. The technology targets deep-brain stimulation lead placement for Parkinson’s disease and other movement disorders, and can be adapted for cranial biopsies, tumor and epilepsy ablations, and targeted intracranial drug delivery. By eliminating the need to shuttle patients between the operating room and imaging suite, the system seeks to make procedures faster, safer, and more precise, lowering both risk and cost. The company plans to layer artificial intelligence onto the platform so it can learn from surgical data, optimize workflows, and provide predictive guidance. AiM estimates its initial DBS market opportunity at $7.9 billion. Including the new capital, the company has secured over $11.3 million in equity funding, supplemented by significant federal grants. The fresh funds will support first-in-human trials, regulatory progress, and expansion of strategic partnerships.
- Thrive Bioscience
Participated · Seed · Aug 2015
Thrive Bioscience develops and is commercializing solutions designed to increase the speed, quality and cost‑effectiveness of cell culture. Its technologies target applications including growing stem cells, drug discovery and basic research. The company closed a $4.0M seed financing to support its efforts. Thrive intends to use the funds to accelerate commercialization of its solutions. The business is led by President and Co‑Founder Thomas Forest Farb and Chief Scientific Officer and Co‑Founder Alan P. Blanchard, Ph.D. Thrive is based in Beverly, Massachusetts and is part of the North Shore InnoVentures incubator.